Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.44 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.37 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30522978 | 0.86 | NR1H2 (0.43) | RIPK1PDE5ATSHRNPSR1 | |
| SCHEMBL25324862 | 0.86 | NR1H2 (0.43) | RIPK1PDE5ATSHRNPSR1 | |
| SCHEMBL25324866 | 0.86 | NR1H2 (0.43) | RIPK1PDE5ATSHRNPSR1 | |
| SCHEMBL25327354 | 0.86 | RIPK1 (0.58) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25327435 | 0.86 | RIPK1 (0.53) | RIPK1PDE5ASLC6A9PDK1PDK2 | |
| SCHEMBL25327034 | 0.83 | SLC6A9 (0.39) | RIPK1PDE5ASLC6A9TSHRNPSR1 | |
| SCHEMBL25326988 | 0.81 | RIPK1 (0.53) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL25327344 | 0.80 | TMEM97 (0.45) | RIPK1SLC6A9 | |
| SCHEMBL25328951 | 0.78 | RIPK1 (0.45) | RIPK1PDK1PDK2PDK3PDK4 | |
| SCHEMBL30522918 | 0.77 | NR1H2 (0.48) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |